Marker Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 26, 2024
MRKR$0.95-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the Years Ended | ||||||
| · · December 31, | ||||||
| | 2023 | 2022 | ||||
| Cash Flows from Operating Activities: | | | | | | |
| Net loss | | $(8,236,814) | | $(29,930,694) | ||
| Less: gain (loss) from discontinued operations, net of $63,000 in tax | | | 5,809,081 | | | (10,154,779) |
| Net loss from continuing operations | | | (14,045,895) | | | (19,775,915) |
| Reconciliation of net loss to net cash used in operating activities: | | | | |||
| Stock-based compensation | | 858,269 | | 3,304,634 | ||
| Gain on lease termination | | | — | | | (278,681) |
| Changes in operating assets and liabilities: | | | ||||
| Prepaid expenses and deposits | | 861,113 | | 104,147 | ||
| Other receivables | | 1,374,189 | | (2,401,767) | ||
| Accounts payable and accrued expenses | | 611,262 | | (1,319,710) | ||
| Deferred revenue | | | — | | | (1,146,186) |
| Net cash used in operating activities - continuing operations | | | (10,341,062) | | | (21,513,478) |
| Net cash used in operating activities - discontinued operations | | | (6,098,899) | | | (5,458,675) |
| Net cash used in operating activities | | (16,439,961) | | (26,972,153) | ||
| Cash Flows from Investing Activities: | | | | |||
| Net cash provided by (used in) investing activities - discontinued operations | | | 18,664,122 | | | (4,945,136) |
| Net cash provided by (used in) investing activities | | 18,664,122 | | (4,945,136) | ||
| Cash Flows from Financing Activities: | | | ||||
| Proceeds from issuance of common stock, net | | 1,014,640 | | 202,130 | ||
| Proceeds from stock options exercise | | 90,477 | | — | ||
| Net cash provided by financing activities | | 1,105,117 | | 202,130 | ||
| Net increase (decrease) in cash and cash equivalents | | 3,329,278 | | (31,715,159) | ||
| Cash and cash equivalents at beginning of the year | | 11,782,172 | | 43,497,331 | ||
| Cash and cash equivalents at end of the year | | $15,111,450 | | $11,782,172 | ||
| · · · · · · | ||||
|---|---|---|---|---|
| | For the Years Ended | |||
| · · December 31, | ||||
| · 2023 · 2022 | ||||
| Supplemental schedule of non-cash financing and investing activities: · · · · · · | ||||
| Capital expenditures in accounts payable | | $— | | $57,607 |
| Issuance of common stock as commitment fee for future financing | | $180 | | $— |
| Changes to right of use assets and lease liability due to close out of operating lease | | $— | | $3,459,332 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.